secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0000950170-22-003130
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q4 revenue $8.4M (+71% YoY); FY22 guidance $40-44M
----------------------------------------------------------

- Q4 2021 revenue $8.4M, up 71% YoY; FY2021 revenue $22.6M, up 54% YoY.
- Q4 net loss $(15.7)M ($(0.58)/diluted share); adjusted net loss $(12.8)M ($(0.47)/share).
- Sold 45 LDDs in Q4, installed base 206; 2,959 LALs sold in Q4.
- Cash and investments $159.3M; long-term debt $39.8M as of Dec 31, 2021.
- FY2022 revenue expected $40-44M; gross margin 35-36%; OpEx $86-90M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022003130/0000950170-22-003130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022003130/rxst-20220308.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer